Katy K. Tsai
Expertise in
6
conditions

Dr. Katy K. Tsai

Hematology | Oncology
Ucsf Health Cancer Symptom Management
1825 4th St, 
San Francisco, CA 
Accepting New Patients
Offers Telehealth
Expertise in
6
conditions
Ucsf Health Cancer Symptom Management
1825 4th St, 
San Francisco, CA 

Overview

Dr. Katy K. Tsai is a medical oncologist who specializes in treating melanoma and other skin cancers. In addition to caring for patients, Tsai conducts clinical trials with two of her colleagues in cutaneous oncology, Dr. Adil Daud and Dr. Alain Algazi, seeking new and better therapies for patients with advanced melanoma or head and neck cancers. She also has a long-standing research interest in quality of life and outcomes for patients receiving immunotherapy. Tsai graduated with a degree in comparative literature from Brown University before earning her medical degree from Brown. She completed a residency in internal medicine at the University of North Carolina at Chapel Hill, followed by a fellowship in medical oncology at UCSF, where she served as chief fellow. Tsai is a member of the American Society of Clinical Oncology. She was born in Taiwan and raised in Toronto.

Dr. Tsai is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Melanoma, Melanoma of the Eye, Merkel Cell Carcinoma, and Uveal Melanoma.

Dr. Tsai is board certified in American Board Of Internal Med/Medical Oncology, Medical Oncology and American Board Of Internal Medicine, Internal Medicine. She is actively involved in clinical research, co-authoring 64 peer reviewed articles and participating in 5 clinical trials. Dr. Tsai is currently accepting new patients.

Graduate Institution

Brown University School Of Medicine, MD

Residency

University of North Carolina Schl of Medicine GME, Internal Medicine

Specialties

Hematology
Oncology

Licenses

Internal Medicine in CA

Board Certifications

American Board Of Internal Med/Medical Oncology, Medical Oncology
American Board Of Internal Medicine, Internal Medicine

Fellowships

University of CA at San Francisco - Hema/Onc GME, Oncology

Hospital Affiliations

Ucsf Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

Ucsf Health Cancer Symptom Management
1825 4th St, San Francisco, CA 94143
Other Locations
Cancer Immunotherapy Toxicity Evaluation (CITE) Program
1825 Fourth St., San Francisco, CA 94158
Melanoma & Skin Cancer Center
1825 Fourth Street, Third Floor, San Francisco, CA 94158

Additional Areas of Focus

Dr. Tsai has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

An Open-Label, Multicenter, Phase 1B/2 Study of RP1 in Solid Organ and Hematopoietic Cell Transplant Recipients With Advanced Cutaneous Malignancies (ARTACUS)
An Open-Label, Multicenter, Phase 1B/2 Study of RP1 in Solid Organ and Hematopoietic Cell Transplant Recipients With Advanced Cutaneous Malignancies (ARTACUS)
Enrollment Status: Active_not_recruiting
Publish Date: April 22, 2026
Intervention Type: Biological
Study Drug: RP1 Genetically-Modified Herpes Simplex Type 1 Virus
Study Phase: Phase 1/Phase 2
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors [IGNYTE]
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2026
Intervention Type: Biological
Study Drugs: RP1, Nivolumab
Study Phase: Phase 2
A Phase I, First-In-Human, Multicenter, Open-Label Dose Escalation and Dose Expansion Study of ABM-1310, as a Monotherapy and a Combination Therapy, Administered Orally in Adult Patients With Advanced Solid Tumors Harboring BRAF Mutations
A Phase I, First-In-Human, Multicenter, Open-Label Dose Escalation and Dose Expansion Study of ABM-1310, as a Monotherapy and a Combination Therapy, Administered Orally in Adult Patients With Advanced Solid Tumors Harboring BRAF Mutations
Enrollment Status: Terminated
Publish Date: May 21, 2024
Intervention Type: Drug
Study Drug: ABM-1310
Study Phase: Phase 1
Phase II Single-arm Multi-center Study of Adjuvant Ipilimumab in Combination With Nivolumab in Subjects With High-risk Ocular Melanoma
Phase II Single-arm Multi-center Study of Adjuvant Ipilimumab in Combination With Nivolumab in Subjects With High-risk Ocular Melanoma
Enrollment Status: Unknown
Publish Date: April 11, 2023
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
A Randomized, Phase 2 Study of Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
A Randomized, Phase 2 Study of Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
Enrollment Status: Completed
Publish Date: December 23, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

64 Total Publications

Stepping on the Gas or Hitting the Brakes: Response-Driven Therapy for Melanoma.
Stepping on the Gas or Hitting the Brakes: Response-Driven Therapy for Melanoma.
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: July 16, 2026
Similar Doctors
Expertise in
12
conditions
Dr. Elliott P. Vichinsky
Hematology | Oncology
Expertise in
12
conditions
Dr. Elliott P. Vichinsky
Hematology | Oncology
Referral may be required

UCSF Benioff Children's Hospital Oakland

747 52nd St, 
Oakland, CA 
 (8.3 miles away)
510-428-3372
Languages Spoken:
English
See accepted insurances

Elliott Vichinsky is a Hematologist and an Oncologist practicing medicine in Oakland, California. Dr. Vichinsky is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, Splenectomy, and Bone Marrow Transplant.

Expertise in
13
conditions
Dr. Ashutosh P. Lal
Hematology | Oncology
Expertise in
13
conditions
Dr. Ashutosh P. Lal
Hematology | Oncology
Referral may be required

UCSF Benioff Children's Hospital Oakland

747 52nd St, 
Oakland, CA 
 (8.3 miles away)
510-428-3374
Languages Spoken:
English, Hindi, Punjabi, Urdu
See accepted insurances
Offers Telehealth

Ashutosh Lal is a Hematologist and an Oncologist practicing medicine in Oakland, California. Dr. Lal is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Thalassemia, Beta Thalassemia, Congenital Hemolytic Anemia, Hemoglobinopathy, and Splenectomy.

Expertise in
11
conditions
Dr. Mark C. Walters
Hematology | Oncology
Expertise in
11
conditions
Dr. Mark C. Walters
Hematology | Oncology
Referral may be required

UCSF Benioff Children's Hospital Oakland

747 52nd St, 
Oakland, CA 
 (8.3 miles away)
510-428-3374
Languages Spoken:
English
See accepted insurances

Mark Walters is a Hematologist and an Oncologist practicing medicine in Oakland, California. Dr. Walters is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Hemoglobinopathy, Congenital Hemolytic Anemia, Sickle Cell Disease, Hemolytic Anemia, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Katy K. Tsai

How do I make an appointment with Dr. Katy K. Tsai?

You can book an appointment with Dr. Katy K. Tsai by calling their office at 415-514-5860. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Katy K. Tsai a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Katy K. Tsai is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Katy K. Tsai specialize in?

While Dr. Katy K. Tsai is a Hematology, they have specific expertise in Melanoma, Melanoma of the Eye, and Merkel Cell Carcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Katy K. Tsai participate in research or clinical trials?

Yes. Dr. Katy K. Tsai has published 64 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Katy K. Tsai's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Katy K. Tsai accept my insurance?

Dr. Katy K. Tsai accepts most major insurance plans, including Anthem BCBS and Blue Shield of California. We recommend calling the office directly at 415-514-5860 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tsai's expertise for a condition
ConditionClose
View All 19 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile